NCT00247481已完成2 期
A Multicentre, Randomised, Double-Blind, Non-Comparative Phase II Trial Of ZD1839 (Iressa™) And Placebo In Combination With Chemotherapy With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 77
- 试验地点
- 6
- 主要终点
- To estimate the overall response rates (complete response [CR] and partial response [PR]) in the ZD1839-treated group and the placebo-treated group.
研究概览
简要总结
This is a multicentre, randomised (2:1), double blind, non-comparative phase II trial of ZD1839 and placebo in combination with chemotherapy in patients with metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed breast cancer at a metastatic stage.
- •Uni- or bi-dimensionally measurable lesions (10 mm or 20 mm) according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria
- •World Health Organisation (WHO) performance status (PS) of 0 to 2
- •Life expectancy of greater than 12 weeks
- •Normal cardiac function (left ventricular ejection fraction [LVEF] by isotopic examination greater than or equal to 55%)
排除标准
- •Symptomatic lepto-meningeal metastasis
- •Concomitant infectious disease
- •Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy
- •Incomplete healing from previous oncologic or other surgery
- •Absolute neutrophil count (ANC) less than 1.5 x 109/litre (L) or platelets less than 100 x 109/L
- •Serum creatinine greater than 1.5 times the ULRR or clearance < 60 ml/min
- •ALT or AST greater than 2.5 times the ULRR
- •ALP > 5 times the ULRR
- •ALP > 2.5 times the ULRR and ALT or AST greater than 1.5 times the ULRR
结局指标
主要结局
To estimate the overall response rates (complete response [CR] and partial response [PR]) in the ZD1839-treated group and the placebo-treated group.
次要结局
- o To assess progression-free survival (PFS) in the ZD1839-treated group and the placebo-treated group.
- o To estimate the duration of response in the ZD1839-treated group and the placebo treated group
- o To estimate overall survival in the ZD1839-treated group and the placebo-treated group
- o To estimate time to treatment failure (TTF) in the ZD1839-treated group and the placebo treated group
研究者
研究点 (6)
Loading locations...
相似试验
终止
2 期
A Study of Telitacicept for Injection (RC18) in Subjects With IgA NephropathyIgA NephropathyNCT04905212RemeGen Co., Ltd.15
尚未招募
2 期
A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisNCT05424887Shanghai Ark Biopharmaceutical Co., Ltd.105
进行中（未招募）
不适用
Investigation of Cogane (PYM50028) in early stage Parkinson's diseaseEUCTR2010-018534-44-HUPhytopharm plc408
进行中（未招募）
不适用
Investigation of Cogane (PYM50028) in early stage Parkinson's diseaseEUCTR2010-018534-44-CZPhytopharm plc408
已完成
2 期
A Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane (PYM50028), a novel, orally active neurotrophic factor inducer, in male and female subjects with early-stage Parkinson's disease administered once daily for 28 WeeksG20Parkinson diseaseDRKS00000756Phytopharm plc425